Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT05536297) enrolled a total of 278 participants across three groups. One group (64 people) received a treatment called ACP every month throughout the whole study. A second group (62 people) had previously received ACP on a mixed schedule — sometimes every month, sometimes every other month — and then switched to receiving it every month. A third group (152 people) had previously received a sham (inactive/dummy) treatment and then switched to receiving ACP every month. The trial was primarily measuring how many participants experienced any unwanted medical events (called adverse events), and secondarily looking at whether the body developed any antibody response to the drug, as well as measuring the levels of ACP in the blood over time. The reported data shows that, when it came to unwanted medical events, 50 out of 64 participants in the first group, 49 out of 62 in the second group, and 129 out of 152 in the third group had at least one such event recorded during the trial. Regarding antibody responses to the drug, the reported data shows that 1 participant in the first group, 0 in the second group, and 2 in the third group developed a detectable antibody response. For blood levels of ACP measured in units called ng/mL (nanograms per millilitre, a measure of how much of the drug was present in the blood), the reported data shows a range of measurements across different time points for each group; notably, the sham group started with very low levels (0.044 ng/mL) before switching to ACP, after which their levels rose to be broadly similar to the other groups (ranging from around 31 to 38 ng/mL across the later time points). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Macular Degeneration Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be aged 50 or older and have been diagnosed with geographic atrophy (a type of eye condition causing vision loss) that affects the centre and/or outer areas of the eye
- You must have fully completed the previous related study called GATHER2 (ISEE2008), including attending the 24-month visit while on the study treatment
- You must be willing and able to sign a new consent form agreeing to take part in this new study
- You must be able to attend all required visits over the 18-month length of this trial
Who may not be able to join:
- You did not complete the previous GATHER2 study through the 24-month visit while on the study treatment (whether that was the active drug or a sham/dummy procedure)
- You had the study drug permanently stopped during the GATHER2 study due to a side effect or medical reaction
- You did not sign up for this new trial within the 90-day enrolment window after the previous study ended
- You are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Astellas Pharma Global Development, Inc.
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.